Stocks › ACAD
ACADIA PHARMACEUTICALS INC
ACAD·Nasdaq·
United States·USD
United States·USD$19.74
-0.37 (-1.84%)
Close · Oct 6, 2026 · Close Prices from Tiingo.com
ACAD
ACADIA PHARMACEUTICALS INC · Nasdaq
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
ACADS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair
Congressional Trades
Recent trades of ACAD by members of U.S. Congress · 3 on record
| Politician | Stock | Type | Filed | Traded | |
|---|---|---|---|---|---|
 Christopher L. JacobsHouse · R · NY |
ACADACADIA PHARMACEUTICALS INC · Stock |
Sale $1,001 - $15,000 |
Jul 28, 2022 | Jun 16, 2022 | Filing ↗ |
| Christopher L. JacobsHouse · R · NY |
ACADACADIA PHARMACEUTICALS INC · Stock |
Sale $1,001 - $15,000 |
Nov 6, 2020 | Sep 8, 2020 | Filing ↗ |
 Gilbert Ray Cisneros, Jr.House · D · CA |
ACADACADIA PHARMACEUTICALS INC · Stock |
Sale $1,001 - $15,000 |
Mar 8, 2019 | Feb 19, 2019 | Filing ↗ |
Whale Activity
Position changes in ACAD reported for 2026-06-30 by 13 tracked institutional filers
- Increased6
- New0
- Held0
- Decreased4
- Closed0
- No prior filing3
| Filer | Shares | Value | Change |
|---|---|---|---|
| BlackRock, Inc. | 22.5M | $569.6M | increased |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 8.8M | $223.6M | increased |
| VANGUARD CAPITAL MANAGEMENT LLC | 5.8M | $145.8M | increased |
| Palo Alto Investors LP | 2.9M | $72.5M | — |
| Palo Alto Investors LP | 2.9M | $72.5M | — |
| Point72 Asset Management, L.P. | 2.4M | $61.6M | decreased |
| CITADEL ADVISORS LLC | 2.2M | $55.2M | increased |
| D. E. Shaw & Co., Inc. | 1.7M | $43.0M | increased |
| RENAISSANCE TECHNOLOGIES LLC | 1.3M | $32.4M | decreased |
| TWO SIGMA INVESTMENTS, LP | 927.0K | $23.5M | increased |
| MILLENNIUM MANAGEMENT LLC | 589.9K | $14.9M | decreased |
| Tetragon Partners GP Ltd | 167.9K | $4.2M | — |
KeyVex tracks a curated set of large 13F filers plus the largest positions in recent filings, so this is a sample of institutional activity, not the whole market.
Insider Trading
Net shares bought (+) or sold (−) on the open market by ACAD insiders, by quarter · Form 4
Recent Insider Transactions
980 transactions on record · newest first
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICER | Sale | −9,292 | $29.34 | $273K | Aug 6, 2026 | Form 4 ↗ |
| Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICER | Sale | −5,000 | $29.00 | $145K | Aug 6, 2026 | Form 4 ↗ |
| Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICER | Sale | −5,849 | $29.00 | $170K | Aug 5, 2026 | Form 4 ↗ |
| Thompson Elizabeth H.Z.EVP, Head of Research & Dev | Sale | −50 | $26.17 | $1K | Jul 30, 2026 | Form 4 ↗ |
| Thompson Elizabeth H.Z.EVP, Head of Research & Dev | Sale | −16.5K | $26.13 | $431K | Jul 30, 2026 | Form 4 ↗ |
| Kihara JamesPRINCIPAL ACCOUNTING OFFICER | Sale | −11.4K | $26.08 | $298K | Jun 26, 2026 | Form 4 ↗ |
| Baker Brothers Life Sciences LPDirector · 10% owner | Grant / award | +18.6K | $0.00 | $0 | May 29, 2026 | Form 4 ↗ |
| Baker Brothers Life Sciences LPDirector · 10% owner | Grant / award | +18.6K | $0.00 | $0 | May 29, 2026 | Form 4 ↗ |
| Ndu AdoraDirector | Option exercise | +8,107 | — | — | May 29, 2026 | Form 4 ↗ |
| GAROFALO ELIZABETH A.Director | Option exercise | +8,107 | — | — | May 29, 2026 | Form 4 ↗ |
| Poole JonathanDirector | Option exercise | +2,010 | — | — | May 29, 2026 | Form 4 ↗ |
| Daly James MDirector | Option exercise | +8,107 | — | — | May 29, 2026 | Form 4 ↗ |
| Brege LauraDirector | Option exercise | +8,107 | — | — | May 29, 2026 | Form 4 ↗ |
| HARRIGAN EDMUNDDirector | Option exercise | +8,107 | — | — | May 29, 2026 | Form 4 ↗ |
| Kihara JamesPRINCIPAL ACCOUNTING OFFICER | Sale | −5,401 | $21.18 | $114K | May 26, 2026 | Form 4 ↗ |
| Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICER | Sale | −3,506 | $21.79 | $76K | May 4, 2026 | Form 4 ↗ |
| Kihara JamesPRINCIPAL ACCOUNTING OFFICER | Sale | −1,332 | $21.79 | $29K | May 4, 2026 | Form 4 ↗ |
| Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICER | Option exercise | +6,815 | — | — | May 1, 2026 | Form 4 ↗ |
| Kihara JamesPRINCIPAL ACCOUNTING OFFICER | Option exercise | +2,596 | — | — | May 1, 2026 | Form 4 ↗ |
| Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICER | Sale | −2,709 | $22.20 | $60K | Apr 7, 2026 | Form 4 ↗ |
Fund Holders
Mutual funds and ETFs holding ACAD · SEC Form N-PORT
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| iShares Core S&P Small-Cap ETF iShares Trust | 7.6M | $193.2M | 0.17% | Jun 30, 2026 |
| VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS | 4.1M | $103.1M | 0.00% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF SPDR SERIES TRUST | 4.0M | $100.6M | 0.94% | Jun 30, 2026 |
| iShares Russell 2000 ETF iShares Trust | 3.3M | $84.7M | 0.10% | Jun 30, 2026 |
| VANGUARD SMALL-CAP INDEX FUND VANGUARD INDEX FUNDS | 2.9M | $74.6M | 0.04% | Jun 30, 2026 |
| First Trust NYSE Arca Biotechnology Index Fund FIRST TRUST EXCHANGE-TRADED FUND | 3.0M | $67.0M | 2.95% | Mar 31, 2026 |
| VANGUARD SMALL-CAP GROWTH INDEX FUND VANGUARD INDEX FUNDS | 1.7M | $43.0M | 0.09% | Jun 30, 2026 |
| VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS | 1.5M | $36.9M | 0.04% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund Fidelity Salem Street Trust | 1.4M | $36.4M | 0.11% | Jul 31, 2026 |
| iShares Biotechnology ETF iShares Trust | 1.2M | $30.3M | 0.33% | Jun 30, 2026 |
Mutual funds and ETFs whose N-PORT filings list ACAD's shares (CUSIP 004225108), each fund at its latest report since Mar 7, 2026, largest positions first. Bonds, options and short positions are left out.
Activist & Passive Stakes
Schedule 13D / 13G beneficial-ownership filings
- STATE STREET CORPORATIONSCHEDULE 13G · passive (13G) · 9.1M shares5.3%
Aug 7, 2026 · ↗
Corporate Lobbying
Estimated quarterly lobbying spending reported under the LDA, filings naming acadia pharmaceuticals as client
- ACADIA PHARMACEUTICALSACADIA PHARMACEUTICALS · 2026 Q2 · HCR, MMM, TAX, TRD$700K
Filing ↗ - TIBER CREEK GROUPACADIA PHARMACEUTICALS, INC. · 2026 Q2 · HCR$80K
Filing ↗ - HOLLAND & KNIGHT LLPACADIA PHARMACEUTICALS INC. · 2026 Q2 · TAX$20K
Filing ↗ - ACADIA PHARMACEUTICALSACADIA PHARMACEUTICALS · 2026 Q1 · HCR, MMM, TAX$600K
Filing ↗ - TIBER CREEK GROUPACADIA PHARMACEUTICALS, INC. · 2026 Q1 · HCR$80K
Filing ↗
Government Contracts
Federal awards to ACADIA PHARMACEUTICALS INC · USAspending
No federal contract awards found for ACADIA PHARMACEUTICALS INC.
U.S. Patents
Recent USPTO applications naming ACADIA PHARMACEUTICALS INC
No USPTO patent applications found for ACADIA PHARMACEUTICALS INC.
Annual Financials
From ACAD's 10-K filings · XBRL
No annual XBRL figures on record for ACAD. KeyVex's fundamentals cover about 130 large companies so far.
Stock Splits
Every split and reverse split in the price history
No stock splits in ACAD's price history.
Material Events (8-K)
Corporate events filed with the SEC
- 8-K · Items 7.01, 8.01, 9.01Reg FD disclosure · Other eventsSep 24, 2026
EDGAR ↗ - 8-K · Items 8.01, 9.01Other eventsSep 11, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsAug 4, 2026
EDGAR ↗ - 8-K · Items 5.02, 5.07, 9.01Officer / director change · Shareholder voteMay 29, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsMay 6, 2026
EDGAR ↗ - 8-K · Items 5.02, 7.01, 9.01Officer / director change · Reg FD disclosureMay 1, 2026
EDGAR ↗
About ACADIA PHARMACEUTICALS INC
From SEC EDGAR company records
Industry (SIC 2834)Pharmaceutical Preparations
SectorHealthcare
HeadquartersSAN DIEGO, CA
IncorporatedDE
SEC CIK0001070494 ↗